Ultragenyx pharmaceutical inc. (RARE)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Operating activities:
Net loss

-119,025

-93,805

-112,994

-99,172

-96,756

-87,826

-87,310

-52,728

30,253

-81,731

-79,227

-72,891

-68,290

-71,287

-64,907

-56,923

-52,757

-55,220

-39,232

-29,787

-21,379

-16,738

-15,849

-13,585

-13,630

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation

20,155

-

-

-

20,221

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation

-

-

-

-

-

21,080

20,667

19,563

18,797

19,541

17,180

16,794

14,499

13,538

13,694

10,860

10,217

9,489

7,896

5,091

2,408

2,001

1,652

946

795

Amortization of discount on investment securities, net

299

1,283

1,971

2,121

839

809

919

674

239

-255

-400

-1,600

549

-612

-1,015

-1,387

-1,828

-1,937

-1,467

-1,268

-965

-1,156

-1,048

-917

-479

Depreciation and amortization

2,852

2,169

2,145

2,106

2,119

2,943

4,355

6,080

6,160

2,514

1,095

1,055

1,161

1,157

1,031

692

544

480

441

262

201

212

194

161

117

Revaluation of convertible preferred stock warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

3,324

Foreign currency remeasurement loss

-474

237

-358

22

-589

544

-7

-1,073

-4,773

-1,413

3,827

3,956

648

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of investment in Arcturus equity securities

7,668

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash collaboration royalty revenue

2,615

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense on liability related to the sale of future royalties

8,082

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain from sale of priority review vouchers

-

-

-

-

-

0

0

40,300

130,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

-3,500

9,702

2,241

5,262

2,899

3,600

-8,270

13,754

-1,501

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Inventory

-149

-2,153

564

2,393

3,647

484

2,214

1,274

1,311

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other assets

15,096

1,262

2,689

2,851

1,414

-6,095

12,836

2,291

5,253

-2,353

-291

461

-930

1,314

1,279

526

4,028

736

2,894

2,553

948

382

602

706

2,391

Receivable related to the Daiichi Sankyo license agreement

125,550

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Right-of-use assets

5,522

-1,405

-1,619

10,320

6,880

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Right-of-use lease assets

5,522

-

-

-

6,880

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable, accrued, and other liabilities

-5,383

-

-

-

-13,081

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Contract liabilities

145,283

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other assets

-

-

-

-

-

-

-40

-157

259

-

-391

-26

-75

-31

422

-617

1,468

-139

-56

9

7

-51

-304

579

187

Accounts payable

-

-

-

-

-

-

-1,969

2,693

-1,317

-

-2,474

3,364

2,989

-1,340

1,017

187

2,638

-1,438

-5,321

4,340

437

484

733

-98

2,058

Lease liabilities

5,511

-1,519

-1,451

11,710

6,812

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued liabilities and other liabilities

-

-

-

-

-

-

2,752

5,544

-12,583

-

4,178

6,745

-12,470

9,601

20,406

4,051

-1,869

4,905

6,986

4,115

664

762

1,490

2,415

-1,186

Net cash used in operating activities

-95,152

-72,039

-88,506

-89,063

-95,775

-55,853

-69,157

-76,078

-89,478

-81,823

-61,993

-48,822

-61,205

-47,680

-28,745

-39,655

-44,895

-40,444

-30,601

-17,273

-17,659

-12,454

-11,030

-10,529

-10,621

Investing activities:
Purchase of property and equipment

14,096

11,500

5,033

5,240

3,059

1,192

1,032

1,377

475

899

1,033

376

485

666

3,001

5,044

1,477

1,923

1,978

595

459

453

439

688

569

Purchase of investments

285,229

82,557

149,179

200,354

260,734

9,747

91,366

147,853

260,830

-3

23,282

119,681

87,527

130,967

88,400

104,993

118,130

146,905

234,917

165,150

77,254

48,030

31,644

41,300

87,998

Proceeds from the sale of investments

16,600

7,618

12,500

0

22,600

-

-

-

-

130,292

6,000

9,227

12,415

46,267

39,957

42,838

11,494

26,011

43,047

7,497

12,766

-

-

-

-

Proceeds from maturities of investments

187,600

153,705

221,026

161,507

140,000

84,500

105,902

51,885

60,277

70,799

48,103

89,753

64,977

77,011

103,612

91,185

131,431

90,630

49,062

47,118

62,240

29,463

15,535

14,512

23,462

Proceeds from sale of priority review vouchers

-

-

-

-

-

0

0

40,322

130,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Decrease (increase) in restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-341

0

1,543

1,373

-1,071

-119

1,358

0

0

0

293

Net cash used in investing activities

-95,125

67,266

79,314

-58,426

-101,193

73,561

16,205

-52,069

-71,028

57,391

29,788

-21,077

-10,620

-7,153

52,509

23,986

21,775

-33,560

-143,715

-111,011

-4,065

-17,021

-13,545

-27,476

-65,398

Financing activities:
Proceeds from the issuance of common stock in connection with the license agreement, net

55,268

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the issuance of common stock in connection with underwritten public offerings, net

-

0

0

0

330,415

0

0

0

270,969

-

-

-

-

-

-

-

-

-22

283,123

2,595

175,440

-324

60,510

10

128,385

Proceeds from the issuance of common stock in connection with at-the-market offering, net

-

0

0

5,523

19,305

10,430

15,837

-19

11,808

64,344

0

25

67,591

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the issuance of common stock from exercise of warrants and equity plan awards, net

380

1,209

904

3,819

3,897

1,812

9,187

13,187

3,642

5,039

1,333

1,501

1,378

4,160

3,385

-25

314

-

-

-

-

-

-

-

-

Principal repayments of financing leases

33

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of preferred stock dividend

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

4,346

Net cash provided by financing activities

55,615

315,443

904

9,342

353,617

12,242

25,024

13,168

286,419

64,439

1,333

1,526

68,969

74,940

63,447

-25

314

887

288,651

2,595

175,440

412

60,510

10

124,039

Effect of exchange rate changes on cash

-623

337

-472

168

-198

145

30

-896

249

361

528

-378

17

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash, cash equivalents and restricted cash

-135,285

311,007

-8,760

-137,979

156,451

30,095

-27,898

-115,875

126,162

40,368

-30,344

-68,751

-2,839

20,042

87,211

-15,694

-22,806

-73,117

114,335

-125,689

153,716

-29,063

35,935

-37,995

48,020

Supplemental disclosures of non-cash information:
Acquired lease liabilities arising from obtaining right-of-use assets

7,397

346

0

13,235

8,280

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Reclassification of warrant liability to equity upon conversion to common stock warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

6,743

Conversion of Series A and Series B preferred stock to common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

129,360